Navigation Links
Topical Spray Helped Men With Premature Ejaculation
Date:4/6/2009

Study found they could delay orgasm six times longer than before

MONDAY, April 6 (HealthDay News) -- A new spray enabled men with premature ejaculation to delay their orgasm six times longer than before, according to a study that included 300 European men.

The men, with clinically diagnosed premature ejaculation, were randomly selected to receive a placebo spray with no active ingredients (100 men) or the PSD502 spray, which contains 7.5 milligrams of lidocaine and 2.5 mg of prilocaine (200 men).

During the three-month study, the men used either the placebo or the PSD502 spray five minutes before intercourse. The men and their partners then used a stopwatch to record the time from vaginal penetration to ejaculation. The men were instructed to abstain from sexual activity or masturbation for 24 hours before each recorded episode of intercourse.

The men who used the PSD502 spray (treatment group) delayed their orgasm from an average of 0.6 minutes to 3.8 minutes, compared to just over 1 minute for those who used the placebo spray. That means the PSD502 spray helped men last 6.3 times longer than normal, compared to 1.7 times longer than normal for those who used the placebo, the study authors said.

The study found that after three months of treatment:

  • 90 percent of the men in the treatment group were able to delay ejaculation for more than 1 minute following vaginal penetration, compared with 54 percent of those in the placebo group.
  • 74 percent of men in the treatment group were able to last 2 minutes before ejaculation, compared with 22 percent of those in the placebo group.
  • 62 percent of men in the treatment group said their orgasms were "good" or "very good" after three months, compared with 20 percent before the start of the study. For men in the placebo group, the figures were 19 percent at the end of the study and 21 percent before the start of the study.
  • More patients and partners in the treatment group reported improvements in perceived control, personal distress, satisfaction with sexual intercourse, and interpersonal problems.

The most common problems noted in the study were loss of erection and a burning sensation in the vagina.

The study findings were published in the April issue of the journal BJU International.

"Premature ejaculation can be a very distressing condition for men and can cause distress, frustration and make them avoid sexual intimacy," lead researcher Professor W. Wallace Dinsmore, of the Royal Victoria Hospital in Belfast, U.K., said in a news release.

"Our study shows that when the PSD502 spray was applied to the man's penis five minutes before intercourse it improved both sexual performance and sexual satisfaction, which are key factors in treating premature ejaculation."

More information

The U.S. National Library of Medicine has more about premature ejaculation.



-- Robert Preidt



SOURCE: BJU International, news release, April 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
2. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
3. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
4. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
5. Topical treatment for age spots, from Harvard Womens Health Watch
6. Summit VetPharm Introduces New Feline Topicals Vectra(TM) for Cats & Kittens and Vectra(TM) for Cats
7. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
8. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
9. Topical Cream Treats Precancerous Lesions of Vulva
10. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
11. Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... , ... May 22, 2017 , ... Galena, Alaska, has ... Arctic Circle made big headlines when it was targeted to build a nuclear plant ... Bush Alaska,” former city manager Marvin L. Yoder describes the journey to get power ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... on Wellocity to empower WeightZone Factor members to track their exercise patterns, monitor ... excellent health education, all on their mobile phones. It also provides social networks ...
(Date:5/21/2017)... , ... May 19, 2017 , ... Chris Cornell, 52, was found dead on the ... one of the most respected lead singers in the rock industry would take his own ... mental illness. FindaTopDoc investigates how mental illness played a role in the death of ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... between ABC Financial Services and financial systems. , Dozens of clubs ... files that are electronically processed through GetLinked into their club’s accounting system , ...
(Date:5/21/2017)... ... 20, 2017 , ... Pot. Reefer. Grass. Mary Jane. No matter what people ... attributes like never before. More than a map, new social marketplace Weedable ... products – and for the first time – each other. A social marketplace like ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... , May 18, 2017  Two Bayer U.S. ... Association (HBA) during its recent 28 th ... City.  The event showcases HBA,s longstanding mission of furthering ... of healthcare. Cindy Powell-Steffen , senior ... U.S. Radiology division, and Libby Howe , a ...
(Date:5/15/2017)... PHILADELPHIA , May 15, 2017 Enterin Inc., ... and developing novel compounds to treat Parkinson,s disease ... The study is a Phase 1/2a randomized, controlled, multicenter study ... sites. It will enroll 50 patients over a 9-to-12-month period. ... doses in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
Breaking Medicine Technology: